Ukr.Biochem.J. 2026; Volume 98, Issue 1, Jan-Feb, pp. 78-87

doi: https://doi.org/10.15407/ubj98.01.078

ROS production and phagocytic activity in human blood phagocytes treated with bacteriophage preparation Pyofag

11.02.2026   Uncategorized

I. Semchuk1, A. Kharina1, N. Korniienko2, M. Rudyk1, R. Dovhyi1,
K. Ostrovska1, K. Liashenko1, Yu. Kortous1, L. Skivka1

1NSC “Institute of Biology and Medicine”,
Taras Shevchenko National University of Kyiv, Ukraine;
2NPBC-UKRAINE LLC;
*e-mail: 03semiramida02@knu.ua

Received: 19 November 2025; Revised: 22 January 2026;
Accepted: 30 January 2026; Available on-line: 23 February 2026

The growing use of bacteriophages in the treatment of antibiotic-resistant infections highlights the need to clarify their direct effects on innate immune cells. This study investigated the effect of polyvalent phage preparation Pyofag on oxidative metabolism and phagocytic function of nonsensitized peripheral blood monocytes and granulocytes under physiological whole-blood conditions. Blood samples from healthy donors were collected using lithium heparin, incubated with Pyofag at phage-to-cell ratios of 1:2, 1:5, and 1:10, centrifuged and the cell pellet was used. ROS production was assessed with the use of DCFDA, phagocytic activity was estimated by fluorescent polystyrene latex beads-uptake intensity. The percentage of phagocytic cells and their mean fluorescence index (MFI) were measured by flow cytometry. It was shown that Pyofag induced statistically significant moderate ROS generation in both phagocyte populations only at the highest dose, remaining markedly lower than that induced by phorbol 12-myristate 13-acetate. Upon Pyofag treatment, only minor reduction in the proportion of phagocytosing monocytes and minor increased in the percentage of phagocytosing granulocytes was observed with no effect on MFI. The mild oxidative activation and stable phagocytic performance observed in Pyofag-treated blood phagocytes point to a noninflammatory, balanced immunomodulatory profile, supporting the safety of this phage preparation for potential systemic administration.

Keywords: , , , , , ,

References:

  1. Anderson M, Panteli D, Mossialos E. Strengthening the EU response to prevention and control of Antimicrobial Resistance: Policy priorities for effective implementation [Internet]. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2024. (Policy Brief, No. 63.) Policy Brief. Available from: https://www.ncbi.nlm.nih.gov/books/NBK610046/
  2. Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: From biological mechanisms to future directions. Cell. 2023;186(1):17-31. PubMed, PubMedCentral, CrossRef
  3. Souza EB, Pinto AR, Fongaro G. Bacteriophages as Potential Clinical Immune Modulators. Microorganisms. 2023;11(9):2222. PubMed, PubMedCentral, CrossRef
  4. Marchi J, Zborowsky S, Debarbieux L, Weitz JS. The dynamic interplay of bacteriophage, bacteria and the mammalian host during phage therapy. iScience. 2023;26(2):106004. PubMed, PubMedCentral, CrossRef
  5. Perea L, Rodríguez-Rubio L, Nieto JC, Zamora C, Cantó E, Soriano G, Poca M, Blanco-Picazo P, Navarro F, Muniesa M, Vidal S. Bacteriophages immunomodulate the response of monocytes. Exp Biol Med (Maywood). 2021;246(11):1263-1268. PubMed, PubMedCentral, CrossRef
  6. Carroll-Portillo A, Lin HC. Bacteriophage and the Innate Immune System: Access and Signaling. Microorganisms. 2019;7(12):625. PubMed, PubMedCentral, CrossRef
  7. Dovhyi R, Rudyk M, Hurmach Ye, Serhiichuk T, Yumyna Yu, Dvukhriadkina A, Ostrovska K, Pjanova D, Skivka L. Polarized activation of human peripheral blood phagocytes by bacteriophage–derived double-stranded RNA (Larifan) in vitro. Biotechnol Acta. 2023;16(6):69-75. CrossRef
  8. Górski A, Międzybrodzki R, Borysowski J, Dąbrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N, Łusiak-Szelachowska M, Kłak M, Jończyk E, Kaniuga E, Gołaś A, Purchla S, Weber-Dąbrowska B, Letkiewicz S, Fortuna W, Szufnarowski K, Pawełczyk Z, Rogóż P, Kłosowska D. Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res. 2012;83:41-71. PubMed, CrossRef
  9. Górski A, Międzybrodzki R, Jończyk-Matysiak E, Kniotek M, Letkiewicz S. Therapeutic Phages as Modulators of the Immune Response: Practical Implications. Clin Infect Dis. 2023;77(Suppl 5):S433-S439. PubMed, CrossRef
  10. Cianci R, Caldarelli M, Brani P, Bosi A, Ponti A, Giaroni C, Baj A. Cytokines Meet Phages: A Revolutionary Pathway to Modulating Immunity and Microbial Balance. Biomedicines. 2025;13(5):1202.
    PubMed, PubMedCentral, CrossRef
  11. Le HT, Venturini C, Lubian AF, Bowring B, Iredell J, George J, Ahlenstiel G, Read SA. Differences in Phage Recognition and Immunogenicity Contribute to Divergent Human Immune Responses to Escherichia coli and Klebsiella pneumoniae Phages. Eur J Immunol. 2025;55(3):e202451543. PubMed, PubMedCentral, CrossRef
  12. Abedon ST. Phage Therapy: Combating Evolution of Bacterial Resistance to Phages. Viruses. 2025;17(8):1094. PubMed, PubMedCentral, CrossRef
  13. Oechslin F. Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy. Viruses. 2018;10(7):351. PubMed, PubMedCentral, CrossRef
  14. Yoo S, Lee K-M, Kim N, Vu TN, Abadie R, Yong D. Designing phage cocktails to combat the emergence of bacteriophage-resistant mutants in multidrug-resistant Klebsiella pneumoniae. Microbiol Spectr. 2024;12(1):e0125823. PubMed, PubMedCentral, CrossRef
  15. 1Abbas S, Kanwar R, Ullah K, Kanwal R, Tajamal M, Aslam MA, Ahmad A, Qadeer A, Huang HY, Chen CC. Bacteriophage therapy: a possible alternative therapy against antibiotic-resistant strains of Klebsiella pneumoniae. Front Microbiol. 2025;16:1443430. PubMed, PubMedCentral, CrossRef
  16. Anastassopoulou C, Panagiotopoulos AP, Ferous S, Tsakris A. Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules. J Antimicrob Chemother. 2025;80(11):2892-2901. PubMed, PubMedCentral, CrossRef
  17. Damascena HL, Silveira WAA, Castro MS, Fontes W. Neutrophil Activated by the Famous and Potent PMA (Phorbol Myristate Acetate). Cells. 2022;11(18):2889. PubMed, PubMedCentral, CrossRef
  18. Tan HY, Wang N, Li S, Hong M, Wang X, Feng Y. The Reactive Oxygen Species in Macrophage Polarization: Reflecting Its Dual Role in Progression and Treatment of Human Diseases. Oxid Med Cell Longev. 2016;2016:2795090. PubMed, PubMedCentral, CrossRef
  19. Larsen EC, DiGennaro JA, Saito N, Mehta S, Loegering DJ, Mazurkiewicz JE, Lennartz MR. Differential requirement for classic and novel PKC isoforms in respiratory burst and phagocytosis in RAW 264.7 cells. J Immunol. 2000;165(5):2809-2817. PubMed, CrossRef
  20. Dovhyi R, Dvukhriadkina A, Ostrovska K, Rudyk M, Verhovcova I, Vaivode K, Pjanova D, Ostapchenko L, Skivka L. Bacteriophage derived dsRNA induces polarized activation of alveolar macrophages from Balb/c and C57Bl/6 mice in vitro in sex- and age-dependent manner. Cell Immunol. 2025;408:104916. PubMed, CrossRef
  21. Picoli SU, Röhnelt NMS, Schenkel TS. Bacteriophages as Anti-Methicillin Resistant Staphylococcus aureus Agents. Infectious Diseases. IntechOpen; 2021. CrossRef
  22. Poniatovskyi V, Bondarchuk O, Prystupiuk M, Smikodub O, Shyrobokov V. Bacteriophages against methicillin resistant Staphylococcus aureus strains. Med Prspekt. 2020;25(4):73-80. CrossRef
  23. Rózsa Á, Orosz L, Szemerédi N, Spengler G, Kecskeméti G, Vágó O, Sárvári KP, Szabó D, Szabó Z, Burián K, Virok DP. Bacteriophage Treatment Induces Phenotype Switching and Alters Antibiotic Resistance of ESBL Escherichia coli. Antibiotics (Basel). 2025;14(1):76. PubMed, PubMedCentral, CrossRef
  24. Zhang S, Liang F, Wan D, Zhang C, Zhang Y, Zhang X, Huang N, Feng K, Liang X, Guo N, Zhang C, Zhou Z, Li Y, Geng J, Liu P, Kong G, Lu S, Li Z. Reactive Oxygen Species-Mediated TRPM2 Activation Facilitates Phagocytosis of Macrophages to Reverse Profibrotic Phenotype. Liver Int. 2025;45(10):e70341. PubMed, PubMedCentral, CrossRef
  25. Przerwa A, Zimecki M, Switała-Jeleń K, Dabrowska K, Krawczyk E, Łuczak M, Weber-Dabrowska B, Syper D, Miedzybrodzki R, Górski A. Effects of bacteriophages on free radical production and phagocytic functions. Med Microbiol Immunol. 2006;195(3):143-150. PubMed, CrossRef
  26. Miernikiewicz P, Dąbrowska K. Endocytosis of Bacteriophages. Curr Opin Virol. 2022;52:229-235. PubMed, CrossRef
  27. Kurzepa A, Dabrowska K, Skaradziński G, Górski A. Bacteriophage interactions with phagocytes and their potential significance in experimental therapy. Clin Exp Med. 2009;9(2):93-100. PubMed, PubMedCentral, CrossRef
  28. Uribe-Querol E, Rosales C. Phagocytosis: Our Current Understanding of a Universal Biological Process. Front Immunol. 2020;11:1066. 82172″], PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.